Core Viewpoint - The recent decline in the innovative drug sector, exemplified by the Hang Seng Innovative Drug Index dropping over 13%, raises questions about whether this downturn is a genuine setback or a temporary market correction [2][3]. Group 1: Policy Changes - The National Medical Products Administration (NMPA) announced a significant reduction in clinical trial review times from 60 days to 30 days, effectively speeding up the approval process by 50% [2]. - This policy change is expected to enhance the efficiency of drug development and encourage companies to shift from a "follower" to a "leader" position in the market [2][3]. Group 2: Capital Market Dynamics - The China Securities Regulatory Commission (CSRC) has reintroduced a listing standard for unprofitable companies on the STAR Market, which is seen as a shift in capital market dynamics favoring genuine innovation over mere scale [2]. - This reopening of the capital market is anticipated to provide biotech companies with the necessary financial backing to compete with international giants [2][3]. Group 3: Payment and Insurance Developments - The integration of commercial insurance and the opening of self-pay channels are set to significantly improve the reimbursement rates for innovative drugs, targeting an 80% reimbursement rate by 2025 in 60 cities [3]. - This development is crucial for drug companies as it allows them to recover R&D investments and encourages further innovation [3]. Group 4: Market Sentiment and Valuation - The recent market downturn is attributed to high trading congestion and inflated valuations, with some stocks reaching a sales multiple of 15 times [3]. - Despite the decline, leading companies like BeiGene and CanSino Biologics still maintain competitive valuations compared to their international peers, indicating potential for recovery [3]. Group 5: Future Outlook - The current market fluctuations are viewed as a necessary correction, with the innovative drug sector poised for long-term growth driven by supportive policies and technological advancements [3]. - The ongoing demand driven by an aging population and the strategic positioning of Chinese companies in advanced therapies suggest a promising future for the sector [3].